Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ibrutinib

FDA-approved product (capsule, oral), marketed as Ibrutinib, Imbruvica.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ibrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Macroglobulinemia
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ibrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ibrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

    NCT02007044 · start 2013-12-06

    Registered record
    Registry ID
    NCT02007044
    Conditions
    Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma
    Interventions
    Ibrutinib; Quality-of-Life Assessment; Questionnaire Administration; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-12-06
    Completion
    2028-06-30
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma
    InterventionIbrutinib; Quality-of-Life Assessment; Questionnaire Administration; Rituximab
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

    NCT01962792 · start 2013-12

    Registered record
    Registry ID
    NCT01962792
    Conditions
    Multiple Myeloma
    Interventions
    Ibrutinib; Carfilzomib; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-12
    Completion
    2019-03
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionIbrutinib; Carfilzomib; Dexamethasone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

    NCT01841723 · start 2013-04-30

    Registered record
    Registry ID
    NCT01841723
    Conditions
    Hairy Cell Leukemia; Hairy Cell Leukemia Variant; Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Ibrutinib; Ultrasound Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-04-30
    Completion
    2029-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHairy Cell Leukemia; Hairy Cell Leukemia Variant; Recurrent Hairy Cell Leukemia; Recurrent Hairy Cell Leukemia Variant
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

    NCT01722487 · start 2013-03

    Registered record
    Registry ID
    NCT01722487
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Ibrutinib; Chlorambucil
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2015-05
    Enrolment
    269

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionIbrutinib; Chlorambucil
    PhasePhase 3
    Registry statusCompleted

  • Phase 1b Safety and Efficacy Study of TRU-016

    NCT01644253 · start 2012-09

    Registered record
    Registry ID
    NCT01644253
    Conditions
    Chronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma
    Interventions
    20 mg/kg TRU-016 + Rituximab; 10 mg/kg TRU-016 + Rituximab; TRU-016 20 mg/kg + Obinutuzumab; TRU-016 6-20 mg/kg + idelalisib + rituximab; TRU-016 10-20 mg/kg + ibrutinib; TRU-016 10-20 mg/kg + bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-09
    Completion
    2021-04-21
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Peripheral T-cell Lymphoma
    Intervention20 mg/kg TRU-016 + Rituximab; 10 mg/kg TRU-016 + Rituximab; TRU-016 20 mg/kg + Obinutuzumab; TRU-016 6-20 mg/kg + idelalisib + rituximab +2 more
    PhasePhase 1
    Registry statusTerminated